Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020798 | 1.00 | PTGER2 (0.38) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL16504095 | 1.00 | PTGER2 (0.38) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL2738742 | 1.00 | PTGER2 (0.38) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL14098097 | 1.00 | PTGER2 (0.38) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL2738741 | 1.00 | PTGER2 (0.38) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL2738740 | 0.89 | PTGER2 (0.33) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL14098092 | 0.89 | PTGER2 (0.33) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL16504092 | 0.89 | PTGER2 (0.33) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL10020800 | 0.89 | PTGER2 (0.33) | PTGER2PDE4DTBXA2RPTGER4ALDH1A1 | |
| SCHEMBL3439806 | 0.85 | PTGER2 (0.40) | PTGER2TBXA2RPTGER4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748454-B2 | Anti-constipation composition | SUCAMPO AG (CH) | 2014-06-10 | — | — | US | disclosed |
| US-20120237598-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2012-09-20 | — | — | US | disclosed |
| US-8143316-B2 | Method for treating peripheral vascular diseases | SUCAMPO AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8114890-B1 | Anti-constipation composition | SUCAMPO AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SUCAMPO AG (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022152-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | PTGER2 1227/4885PDE4D 436/4885TBXA2R 1845/4885 |
| US-20120237598-A1 | ANTI-CONSTIPATION COMPOSITION | SLC10A2, FABP6, VIP | PTGER2 1227/4885PDE4D 436/4885TBXA2R 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.